Equity
€3.7m from €17.4m in 2021
Equity fell by 79% in 4 years.
ExeVir Bio
Lifetime
5 annual accounts with figures on one time axispeak €11.9m (2022)
-€1.2m▼ €2.1m
lowest -€27.3m (2021)
-€1.9m▲ €2.9m
peak €17.4m (2021)
€3.7m▼ 34.6%
€85,956▼ 90.6%
peak 10.1 FTE (2022)
1.8 FTE▼ 80.2%
Board16 names since 2020all names
12 directorsVAN BIERVLIET Jérôme and 11 others
Owners7 names in the annual accountsall names
19.02%Fund+ and 2 others
Documentsfilings and deeds
03-07-202628 days before the deadline
2025abbreviated format
Gross margin from €939,421 to -€1.2mLoss of €1.9mStaff from 9.1 FTE to 1.8 FTEResignation: Michel Kazatchkine (director) 03-10New day-to-day manager 28-03Equity from €5.6m to €3.7m
Key points
from the 2025 annual accountsLosses
-€41.0m in five years
Every financial year from 2021 to 2025 closed with a loss. 2021 was the heaviest.
Staff
1.8 FTE from 10.1 in 2022
Between 2022 and 2025, 82% of the full-time equivalents disappeared.
Liquidity
42.60 was 6.61 in 2024
Short-term debts fell from €915,520 to €85,956.
Board
3 joined · 4 left
Board changed. Latest change 17-02-2026 · 8 in office.
Position in the sector
-€1.9m
Lower net result than 91% of companies in research and development. Sector median €1,513 · 271 companies.
Turnover not published (abbreviated format)
Checked score
55
Fair
Financially stronger than 45% of micro companies in research and development (NACE 72)
Probability in this band: 1.5% to 4.2%
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59.
Bankruptcy probability within 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 932 companies (NACE 72, micro).
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.4%
01-2025: 0.4%● unchanged vs 12-2024
02-2025: 0.4%● unchanged vs 01-2025
03-2025: 0.4%● unchanged vs 02-2025
04-2025: 0.5%▲ +0.1 percentage points vs 03-2025
05-2025: 0.5%● unchanged vs 04-2025
06-2025: 0.5%● unchanged vs 05-2025
07-2025: 0.5%● unchanged vs 06-2025highest value
08-2025: 0.4%▼ -0.1 percentage points vs 07-2025
09-2025: 0.4%● unchanged vs 08-2025
10-2025: 0.4%● unchanged vs 09-2025
11-2025: 0.5%▲ +0.1 percentage points vs 10-2025
12-2025: 0.5%● unchanged vs 11-2025
01-2026: 0.2%▼ -0.3 percentage points vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.3%▲ +0.1 percentage points vs 03-2026
05-2026: 0.3%● unchanged vs 04-2026
06-2026: 0.3%● unchanged vs 05-2026
07-2026: 0.3%● unchanged vs 06-2026
08-2026: 0.2%▼ -0.1 percentage points vs 07-2026lowest value
09-2026: 0.2%● unchanged vs 08-2026
10-2026: 0.2%● unchanged vs 09-2026
11-2026: 0.2%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Capped at 59: a net loss of at least half of total assets or of the equity at the start of the financial year
Loss of €1.9m, the second in a row (financial year 2025)
lowers risk
Sector: Scientific research and development (NACE 72)
Liquidity: current ratio 42.60, cash €925,562, halved
Figures for financial year 2025 (filed on 03-07-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro). It does better than 83% of them on solvency, 68% on liquidity, 10% on profitability and 20% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 3,591 companies had the same profile as ExeVir Bio has now. Each dot stands for 9 companies, two years later.
87.3%
were still trading
9.4%
stopped another way
3.0%
went bankrupt
Another 0.3% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of ExeVir Bio itself is lower: 0.2% within 12 months. It rests on far more data about ExeVir Bio than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,591 companies, not a prediction for ExeVir Bio. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €200,000 on 30-day terms, only on tighter conditions
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity is ample, with a current ratio of 42.6 (6.61 in 2024), above the usual 1.5. Short-term debt is 2.3% and cash 24.6% of total assets. 2.3% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
2122232425
2021 to 2025 · latest year -€1.9m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-07-2026, 28 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
28 days early
2024
31 days early
2023
34 days early
2022
45 days early
2021
52 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 5 accounts on average 38 days before the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 June (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
and 3 others
- Fund+ 19.02%equity €124.0m (2025) · 2025 annual accounts of Fund+
- UCB BIOPHARMA 17.89%score 81equity €1.18bn (2025) · 2025 annual accounts of UCB BIOPHARMA
- FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ 13.42%equity €11.45bn (2025) · 2025 annual accounts of FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ
Recent changes
4 directors appointed, 4 resignations, 1 statutory auditor reappointed
Resignations: GARRETT Michael, SPARAXIS, BOLGER Jeanne and BONHEURE Kenneth · Appointments: NOVAK Halina, WHITTAKER Erica, VAN BIERVLIET Jérôme and HEYLEN Stefaan · Reappointment: PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor) · General meeting of 11-02-2026 · Gazette deed
Resignation: Michel Kazatchkine (director)
General meeting of 05-06-2025 · Gazette deed
New day-to-day manager
Michael Cornelius Garrett appointed, Jeanne Bolger resigned · Board meeting of 25-02-2025 · Gazette deed
Resignation: Torsten Mummenbrauer (day-to-day manager)
General meeting of 03-05-2024 · Gazette deed
Comparable companies
same main activity, similar in size and ageThese companies have the same main activity as ExeVir Bio: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €1.2m and €10m, founded between 2019 and 2022.
Official details
Source: KBO- Status
- Active since 10-07-2020Normal situation
- Registered office
- 10 active companies are registered at this address1 started in the 12 months before. Source: KBO register, as of 10 November 2026.
- Activity
- Research and development on biotechnologyNACE 72101
- Joint committee
- 207White-collar workers in the chemical industry · annual accounts 2025
- Establishment units
- 2.309.434.6939052 Ghent, since 10-07-2020
- 2.323.699.9304000 Liège, since 01-01-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 20-11-2020
Annual accounts 2025
- €3.8m▼ 42.5%
- Filing
- Filed on 03-07-2026, 28 days before the end of the filing period
Companies linked to ExeVir Bio
Shareholders
Insights on ExeVir Bio
ExeVir Bio files the abbreviated format. That format states no turnover. The gross margin fell from €2.5m in 2021 to -€1.2m in 2025.
In February 2026, four directors stepped down.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ExeVir Bio
- What is the company number of ExeVir Bio?
- The company number of ExeVir Bio is 0750.495.334. The VAT number is the same number with BE in front: BE 0750.495.334.
- Where is ExeVir Bio based?
- The registered office is at Technologiepark-Zwijnaarde 94, 9052 Ghent.Company details
- What does ExeVir Bio do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of ExeVir Bio?
- ExeVir Bio is a private limited company (BV).
- When was ExeVir Bio founded?
- ExeVir Bio was founded on 10-07-2020.
- Is ExeVir Bio still active?
- Yes, ExeVir Bio is an active enterprise in the KBO register.
- How many employees does ExeVir Bio have?
- ExeVir Bio had an average of 1.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does ExeVir Bio fall under?
- In its 2025 annual accounts, ExeVir Bio states joint committee 207 (White-collar workers in the chemical industry).
- What is the turnover of ExeVir Bio?
- The annual accounts for financial year 2025 state no turnover. The abbreviated format does not require it.
- Is ExeVir Bio profitable?
- In financial year 2025, ExeVir Bio made a loss of €1.9m.
- Where can I find the annual accounts of ExeVir Bio?
- ExeVir Bio filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ExeVir Bio due?
- ExeVir Bio must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.